Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?

Felip E, Martinez P.

Ann Oncol. 2012 Sep;23 Suppl 10:x189-92.

PMID:
22987959
2.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

PMID:
18977553
3.

The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.

Sève P, Reiman T, Dumontet C.

Lung Cancer. 2010 Feb;67(2):136-43. doi: 10.1016/j.lungcan.2009.09.007. Epub 2009 Oct 13. Review.

PMID:
19828208
4.

The role of adjuvant chemotherapy in early-stage and locally advanced non-small cell lung cancer.

Shapiro M.

Cleve Clin J Med. 2012 May;79 Electronic Suppl 1:eS42-5. doi: 10.3949/ccjm.79.s2.09. Review.

PMID:
22614965
5.
6.

Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.

Custodio AB, González-Larriba JL, Bobokova J, Calles A, Alvarez R, Cuadrado E, Manzano A, Díaz-Rubio E.

J Thorac Oncol. 2009 Jul;4(7):891-910. doi: 10.1097/JTO.0b013e3181a4b8fb. Review.

7.

Adjuvant chemotherapy after pulmonary resection for lung cancer.

Mascaux C, Shepherd FA.

Thorac Surg Clin. 2013 Aug;23(3):401-10. doi: 10.1016/j.thorsurg.2013.04.005. Epub 2013 Jun 4. Review.

PMID:
23931022
8.

Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy.

García-Campelo R, Alonso-Curbera G, Antón Aparicio LM, Rosell R.

Expert Opin Pharmacother. 2005 Oct;6(12):2015-26. Review.

PMID:
16197356
9.

MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.

Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, Khan MA, Hainaut P, Pignon JP, Brambilla E, Popper HH, Filipits M, Harris CC, Giaccone G.

Cancer Res. 2010 Nov 1;70(21):8288-98. doi: 10.1158/0008-5472.CAN-10-1348. Epub 2010 Oct 26.

10.

Second-line combination therapies in nonsmall cell lung cancer without known driver mutations.

Bluthgen MV, Besse B.

Eur Respir Rev. 2015 Dec;24(138):582-93. doi: 10.1183/16000617.00002115. Review.

11.

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.

Wallerek S, Sørensen JB.

Eur Respir Rev. 2015 Jun;24(136):340-55. doi: 10.1183/16000617.00005814. Review.

12.

High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.

Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Mol Cancer Ther. 2012 May;11(5):1203-13. doi: 10.1158/1535-7163.MCT-11-0899. Epub 2012 Mar 12.

13.

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.

Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS.

J Clin Oncol. 2010 Oct 10;28(29):4417-24. doi: 10.1200/JCO.2009.26.4325. Epub 2010 Sep 7. Erratum in: J Clin Oncol. 2010 Dec 1;28(34):5126. J Clin Oncol. 2014 Feb 1;32(4):365.

14.

Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.

Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, André F, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Brambilla E.

J Clin Oncol. 2007 Jul 1;25(19):2735-40.

PMID:
17602078
15.
16.

Systemic and targeted therapies for early-stage lung cancer.

Byron E, Pinder-Schenck M.

Cancer Control. 2014 Jan;21(1):21-31. Review.

17.

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.

18.

Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.

Rosell R, Felip E.

Semin Oncol. 2001 Aug;28(4 Suppl 14):37-44. Review.

PMID:
11605182
19.

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

Olaussen KA, Mountzios G, Soria JC.

Curr Opin Pulm Med. 2007 Jul;13(4):284-9. Review.

PMID:
17534174
20.

Molecular predictors of response to chemotherapy in non-small cell lung cancer.

Andrews J, Yeh P, Pao W, Horn L.

Cancer J. 2011 Mar-Apr;17(2):104-13. doi: 10.1097/PPO.0b013e318213f3cf. Review.

PMID:
21427554

Supplemental Content

Support Center